The headline miss is significant but management attributes it to a one-time VEVYE gross-to-net recalibration and reaffirms full-year guidance. Watch Q2 revenue ($71M-$81M guided) as the first proof point of the VEVYE coverage benefit materializing. Key catalysts: BYOOVIZ launch on July 1, IHEEZO retina data at ASRS in July, and QUELL study data in Q4. The expanded sales force (100+ reps) should drive H2 acceleration. Near-term risk: operating cash burn and debt of $292M on $28M equity.
Price Chart
Executive Summary
Harrow reported Q1 2026 revenue of $44.2M (-8% YoY), missing consensus of $52.5M, and a GAAP net loss of $27.6M (-$0.74/share) vs. consensus EPS of -$0.43. The miss was driven by a non-recurring ~$8M gross-to-net adjustment on VEVYE from new commercial coverage. However, full-year 2026 guidance was reaffirmed at $350M-$365M revenue and $80M-$100M Adjusted EBITDA, and VEVYE prescription metrics (NRx +25% QoQ, market share ~14%) showed strong underlying demand. The stock will likely trade on the guidance reaffirmation and demand acceleration narrative, but the headline miss and negative cash flow from operations (-$9.0M) create near-term headwinds.
Key Financial Metrics
Key Facts
- Q1 2026 revenue $44.2M, down 8% YoY from $47.8M, missing consensus of $52.5M
- GAAP net loss $27.6M (-$0.74/share) vs consensus EPS -$0.43
- VEVYE revenue $20.9M, impacted by ~$8M non-recurring gross-to-net adjustment from new commercial coverage
- Full-year 2026 guidance reaffirmed: revenue $350M-$365M, Adjusted EBITDA $80M-$100M
- Q2 2026 revenue guided $71M-$81M
- VEVYE record quarterly NRx (+25% QoQ) and TRx (+11% QoQ); surpassed XIIDRA on monthly TRx basis with ~14% market share
- IHEEZO unit demand +18% YoY; TRIESENCE unit demand +136% YoY (6th consecutive quarter of growth)
- Cash and cash equivalents $94.6M; operating cash flow -$9.0M vs +$19.7M in Q1 2025
- Gross margin declined to 61% from 68% YoY due to VEVYE net pricing pressure and lower compounding facility utilization
- Adjusted EBITDA -$12.7M vs -$2.0M in Q1 2025
Financial Impact
Q1 revenue miss of ~$8.3M vs consensus; GAAP net loss widened by $9.8M YoY; full-year guidance implies H2-weighted revenue acceleration to ~$203M-$226M
Risk Factors
- Q1 revenue miss and negative operating cash flow (-$9.0M) could pressure near-term sentiment
- VEVYE gross-to-net dynamics may take longer to normalize than guided
- High debt load ($292M loans payable) vs. thin equity base ($28M) creates financial leverage risk
- IHEEZO pass-through payment loss in ASC setting (April 2026) creates headwind that in-office expansion must offset
- Compounding revenue declining 10-20% in 2026 as expected shift to branded products occurs
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-022227 |
| Exhibit: ex99-1.htm | 0001493152-26-022227 |
| Document: form8-k.htm | 0001493152-26-022227 |
| Document: 0001493152-26-022227-index-headers.html | 0001493152-26-022227 |
| Document: 0001493152-26-022227-index.html | 0001493152-26-022227 |
| Document: 0001493152-26-022227.txt | 0001493152-26-022227 |
| 8-K Data (Synthetic) | 0001493152-26-022227 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 5, 2026 21d ago | 8-K | $30.58 $30.35 | ▼ −0.75% | ▼ −1.30% | $28.52 (−6.74%) |
Oct 5, 2026 21d ago | Press Release | $30.58 $30.35 | ▼ −0.75% | ▼ −1.30% | $28.52 (−6.74%) |
Aug 10, 2026 10w ago | 8-K | $39.42 $39.36 | ▼ −0.15% | ▼ −0.40% | $28.52 (−27.65%) |
Aug 10, 2026 10w ago | Press Release | $39.42 $39.36 | ▲ +0.15% | ▲ +0.40% | $28.52 (+27.65%) |
Aug 6, 2026 11w ago | 8-K | $39.92 $40.44 | ▲ +1.30% | ▲ +0.69% | $28.52 (−28.56%) |
Jul 27, 2026 13w ago | Press Release | $37.46 | awaiting T+1 | — | $28.52 (−23.87%) |
Jul 20, 2026 14w ago | Press Release | $44.45 $43.71 | ▼ −1.66% | ▼ −2.50% | $28.52 (−35.84%) |
Jun 11, 2026 19w ago | Institutional Cluster | $37.64 $38.93 | ▲ +3.43% | ▲ +1.66% | $28.52 (−24.23%) |
Jun 11, 2026 19w ago | Institutional Cluster | $37.65 $37.64 | ▼ −0.03% | ▼ −0.57% | $28.52 (−24.25%) |
Jun 3, 2026 20w ago | 8-K | $33.32 $34.69 | ▲ +4.11% | ▲ +3.71% | $28.52 (−14.41%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers